A share price of Kymera Therapeutics Inc [KYMR] is currently trading at $47.74, up 1.90%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The KYMR shares have gain 6.14% over the last week, with a monthly amount glided 3.40%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Kymera Therapeutics Inc [NASDAQ: KYMR] stock has seen the most recent analyst activity on December 02, 2024, when Wells Fargo upgraded its rating to a Overweight but kept the price target unchanged to $57 for it. Previously, Stephens started tracking the stock with Overweight rating on November 18, 2024, and set its price target to $65. Wolfe Research upgraded its rating to a Outperform but stick to its price target of $65 on August 26, 2024. Oppenheimer initiated its recommendation with a Outperform and recommended $53 as its price target on April 22, 2024. In a note dated January 04, 2024, JP Morgan upgraded an Overweight rating on this stock.
Kymera Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $19.73 and $53.27. Currently, Wall Street analysts expect the stock to reach $53 within the next 12 months. Kymera Therapeutics Inc [NASDAQ: KYMR] shares were valued at $47.74 at the most recent close of the market. An investor can expect a potential return of 11.02% based on the average KYMR price forecast.
Analyzing the KYMR fundamentals
Trailing Twelve Months sales for Kymera Therapeutics Inc [NASDAQ:KYMR] were 87.56M which represents -20.88% decline. Gross Profit Margin for this corporation currently stands at 0.93% with Operating Profit Margin at -2.23%, Pretax Profit Margin comes in at -1.91%, and Net Profit Margin reading is -1.91%. To continue investigating profitability, this company’s Return on Assets is posted at -0.16, Equity is -0.25 and Total Capital is -0.2. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 47.14 points at the first support level, and at 46.54 for the second support level. However, for the 1st resistance point, the stock is sitting at 48.85, and for the 2nd resistance point, it is at 49.95.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Kymera Therapeutics Inc [NASDAQ:KYMR] is 8.55. As well, the Quick Ratio is 8.55, while the Cash Ratio is 1.66. Considering the valuation of this stock, the price to sales ratio is 35.30, the price to book ratio is 3.46.
Transactions by insiders
Recent insider trading involved Esposito Pamela, Director, that happened on Dec 02 ’24 when 2500.0 shares were sold. Director, PAMELA ESPOSITO completed a deal on Dec 02 ’24 to buy 2500.0 shares. Meanwhile, Director Esposito Pamela sold 13500.0 shares on Sep 17 ’24.
